At LSI 2021, Jennifer McCaney PhD (Co-Executive Director UCLA Biodesign) & Kwame Ulmer (Venture Partner at Wavemaker Three-Sixty Health) sit down with Benjamin Glenn of A Matter of Innovation to discuss the new UCLA Biodesign curriculum and their landmark study which asks the question:
"What does it take to bring a novel medical technology to market in the year 2021?"
A variety of interesting healthcare topics are also explored in this in-depth interview. AMOI Website
Benjamin Glenn is nationally recognized innovation strategist, speaker and coach based in the Silicon Valley. His work is keenly focused on helping entrepreneurs and innovators in enterprises big and small in our regulated industries identify, develop and maintain competitive advantages. Particularly with regard to our rapidly evolving health care sector, Benjamin's work is highlighted in Biodesign: The Process of Innovating Medical Technologies, a program he has served for over a decade.
Benjamin strongly believes in the increasing importance, and even the necessity, of creating and training a while array of multi-disciplinary teams. Benjamin's passionate presentations often focus on how professionals from different disciplines can successfully work together to create the products and services of the modern economy.
In his presentations, Benjamin draws on his diverse experiences growing up in Texas, serving in the military and working as a Silicon Valley patent attorney. His unique, humorous and often metaphor-ladened insights also draw from over two decades of advising clients on strategic, commercial, innovation and product development issues. As a result, his engaging style has inspired and entertained audiences at leading innovation and entrepreneurial programs nationwide including:
Stanford University BioDesign Program, UC San Francisco, Johns Hopkins University and Northwestern University, along with accelerator and incubator programs such as Matter Chicago, Texas Medical Center’s TMCx, South By SouthWest, VentureWell, Village Capital, Kauffman Foundation, Singularity University, and MedTech Innovator.
Benjamin Glenn is nationally recognized innovation strategist, speaker and coach based in the Silicon Valley. His work is keenly focused on helping entrepreneurs and innovators in enterprises big and small in our regulated industries identify, develop and maintain competitive advantages. Particularly with regard to our rapidly evolving health care sector, Benjamin's work is highlighted in Biodesign: The Process of Innovating Medical Technologies, a program he has served for over a decade.
Benjamin strongly believes in the increasing importance, and even the necessity, of creating and training a while array of multi-disciplinary teams. Benjamin's passionate presentations often focus on how professionals from different disciplines can successfully work together to create the products and services of the modern economy.
In his presentations, Benjamin draws on his diverse experiences growing up in Texas, serving in the military and working as a Silicon Valley patent attorney. His unique, humorous and often metaphor-ladened insights also draw from over two decades of advising clients on strategic, commercial, innovation and product development issues. As a result, his engaging style has inspired and entertained audiences at leading innovation and entrepreneurial programs nationwide including:
Stanford University BioDesign Program, UC San Francisco, Johns Hopkins University and Northwestern University, along with accelerator and incubator programs such as Matter Chicago, Texas Medical Center’s TMCx, South By SouthWest, VentureWell, Village Capital, Kauffman Foundation, Singularity University, and MedTech Innovator.
Biography coming soon...
Talk to the FDA Before You Talk to the FDA
MedTech Impact Partners empowers medtech innovators with the best people, processes, and tools to bring their products to life. We help companies navigate the FDA to bring medical technologies to patients faster.
Kwame Ulmer is a venture partner at Wavemaker Three-Sixty Health - the leading Southern-California based, early stage venture capital firm (Seed and Series A) focused on the healthcare industry. He leads the medtech practice and participates in all aspects of fund management (e.g. deal sourcing, diligence, negotiation and advising portfolio company management teams).
Kwame brings twenty years of experience evaluating medical technologies in the government and private sector, and serving in senior operating roles at medical device companies. He has personally evaluated more than 1,000 medical technologies in his career. Kwame spent 12 years at the U.S. Food and Drug Administration (FDA) in progressive leadership roles, including Deputy Director and Branch Chief. He also served as Vice President, Regulatory Affairs and Quality Assurance at Implant Direct, a Danaher Corporation operating company.
Kwame serves on the board of the University of Virginia Licensing and Ventures Group and the California Life Sciences. He is also a lecturer and researcher in MedTech Innovation at the University of California, Los Angeles. Kwame founded MedTech Color, a nonprofit with a mission to advance the representation of persons of color in the medical device industry. He earned his B.S. in Physics from Lincoln University, and has two Masters degrees from the University of Virginia, in Materials Engineering and Business Administration.
Talk to the FDA Before You Talk to the FDA
MedTech Impact Partners empowers medtech innovators with the best people, processes, and tools to bring their products to life. We help companies navigate the FDA to bring medical technologies to patients faster.
Kwame Ulmer is a venture partner at Wavemaker Three-Sixty Health - the leading Southern-California based, early stage venture capital firm (Seed and Series A) focused on the healthcare industry. He leads the medtech practice and participates in all aspects of fund management (e.g. deal sourcing, diligence, negotiation and advising portfolio company management teams).
Kwame brings twenty years of experience evaluating medical technologies in the government and private sector, and serving in senior operating roles at medical device companies. He has personally evaluated more than 1,000 medical technologies in his career. Kwame spent 12 years at the U.S. Food and Drug Administration (FDA) in progressive leadership roles, including Deputy Director and Branch Chief. He also served as Vice President, Regulatory Affairs and Quality Assurance at Implant Direct, a Danaher Corporation operating company.
Kwame serves on the board of the University of Virginia Licensing and Ventures Group and the California Life Sciences. He is also a lecturer and researcher in MedTech Innovation at the University of California, Los Angeles. Kwame founded MedTech Color, a nonprofit with a mission to advance the representation of persons of color in the medical device industry. He earned his B.S. in Physics from Lincoln University, and has two Masters degrees from the University of Virginia, in Materials Engineering and Business Administration.
At LSI 2021, Jennifer McCaney PhD (Co-Executive Director UCLA Biodesign) & Kwame Ulmer (Venture Partner at Wavemaker Three-Sixty Health) sit down with Benjamin Glenn of A Matter of Innovation to discuss the new UCLA Biodesign curriculum and their landmark study which asks the question:
"What does it take to bring a novel medical technology to market in the year 2021?"
A variety of interesting healthcare topics are also explored in this in-depth interview. AMOI Website
Market Intelligence
Schedule an exploratory call
Request Info17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy